Vanda Pharmaceuticals (VNDA) shares moved lower today after a negative report from market research firm Aurelius Value. Aurelius disclosed that it holds a short position in the stock, and alleges that VNDA’s CEO has engaged in fraudulent schemes along with his company as a whole. Here’s a recap.
Read Similar Articles
We had a great example of a swing buy entry in NIO, Inc., the electric car company (Ticker: NIO). It’s based on a break out pattern on an hourly chart and confirmed with a daily chart. Click the video below to learn more details: Grab a free day pass to one of our live […]Read Article
The VIX and VXX are both very popular trading vehicles for trading volatility. But, unlike the perceptions of many traders, they are not exactly interchangeable. There are many similarities and more importantly, some very important differences. Click the video below to learn more details: Grab a free day pass to one of our live signal […]Read Article
We believe that some banks are in a position to make the next leg up? Why? You ask. Unlike your conventional banks, some banks like Goldman Sachs, JP Morgan, Citibank and, Morgan Stanley have resources that many conventional banks do not. They have MASSIVE trading entities. They are not simply a place to park […]Read Article